Breaking News Instant updates and real-time market news.

AVXS

AveXis

$44.55

2.36 (5.59%)

07:42
10/06/16
10/06
07:42
10/06/16
07:42

AveXis attractive acquisition target, price target to $71 at Goldman

Goldman analyst Salveen Richter said AveXis has two approaching catalysts coming up, the AVXS-101 update in SMA Type 1 at the World Muscle Society, or WMS, on October 8, and clarity on the AVXS-101 pivotal trial design in late October/early November. The analyst expects positive WMS data and raaised his probability of success to 60% from 45%. He expects compelling motor milestone data and pivotal trial visibility to make AveXis an attractive acquisition target and raised his price target to $71 from $46 on shares and reiterated his Buy rating.

  • 06

    Nov

AVXS AveXis
$44.55

2.36 (5.59%)

08/17/16
WELS
08/17/16
UPGRADE
WELS
Outperform
AveXis upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded AveXis (AVXS) to Outperform after speaking to five experts in spinal muscular atrophy. The experts were impressed with both Ionis Pharmaceuticals (IONS)/Biogen's (BIIB) nusinersen and AveXis' gene therapy AVXS101, and suggested that likely incomplete restoration of normal neuromuscular phenotype could prompt combination use of both treatments, Birchenough tells investors in a research note. The analyst raised his price target range for AveXis shares to $56-$61 from $30-$32. The stock closed yesterday down $1.91 to $41.66.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies thinks it found baby in AveXis trial that is walking
Jefferies analyst Biren Amin believes a video posted online of a baby walking has a "strong likelihood" of being a patient in AveXis' AVXS-101 trial. AVXS-101 is a gene therapy candidate in Phase I testing for spinal muscular atrophy. The near 20 month old's achievement to walk "is significant" given that she is a Type 1 SMA baby with 2 copy number and would not in any normal circumstance be expected to walk, Amin tells investors in a research note. The analyst points out that his finding online comes ahead of AveXis' plan to disclose patient data on motor milestones from its Phase 1 trial later this year. To reflect increased confidence in AVXS-101's prospects, Amin raised his price target for the shares to $50 from $42. The clinical-stage gene therapy company, formerly known as Biolife Cell Bank, closed Friday up 83c to $41.72.
09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.

TODAY'S FREE FLY STORIES

ASML

ASML

$199.18

12.8 (6.87%)

09:04
01/18/18
01/18
09:04
01/18/18
09:04
Recommendations
ASML analyst commentary  »

ASML price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNN

Smith & Nephew

$34.98

0.08 (0.23%)

09:04
01/18/18
01/18
09:04
01/18/18
09:04
Hot Stocks
Smith & Nephew's eCAP reduces hospital readmission »

Smith & Nephew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$158.41

0.52 (0.33%)

09:03
01/18/18
01/18
09:03
01/18/18
09:03
Hot Stocks
Honeywell to supply United Airlines with cockpit technologies for new airplanes »

Honeywell cockpit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

  • 25

    Jun

CLVS

Clovis

$54.93

-0.48 (-0.87%)

09:02
01/18/18
01/18
09:02
01/18/18
09:02
Recommendations
Clovis analyst commentary  »

Clovis price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 08

    Feb

NKE

Nike

$63.81

0.39 (0.61%)

09:01
01/18/18
01/18
09:01
01/18/18
09:01
Hot Stocks
Nike names Dirt-Jan van Hameren as VP, Chief Marketing Officer »

NIKE announced Dirk-Jan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPC

Edgewell Personal Care

$60.96

-1.06 (-1.71%)

09:01
01/18/18
01/18
09:01
01/18/18
09:01
Hot Stocks
Edgewell Personal Care to acquire Jack Black, terms not disclosed »

Edgewell Personal Care…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

XOM

Exxon Mobil

$88.00

1.03 (1.18%)

09:01
01/18/18
01/18
09:01
01/18/18
09:01
Hot Stocks
ExxonMobil acquires exploration acreage offshore Ghana »

ExxonMobil announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECC

Eagle Point Credit

$19.13

-0.39 (-2.00%)

09:01
01/18/18
01/18
09:01
01/18/18
09:01
Syndicate
Eagle Point Credit 1.95M share Spot Secondary priced at $18.25 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

ICE

IntercontinentalExchange

$74.80

0.22 (0.29%)

09:01
01/18/18
01/18
09:01
01/18/18
09:01
Hot Stocks
IntercontinentalExchange, Blockstream launch data feed for cryptocurrencies »

Intercontinental Exchange…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JXSB

Jacksonville Bancorp

09:00
01/18/18
01/18
09:00
01/18/18
09:00
Hot Stocks
Breaking Hot Stocks news story on Jacksonville Bancorp »

Jacksonville Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLYA

Playa Hotels & Resorts

$11.31

0.03 (0.27%)

09:00
01/18/18
01/18
09:00
01/18/18
09:00
Syndicate
Playa Hotels & Resorts 6M share Block Trade priced at $10.80 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

RARX

RA Pharmaceuticals

09:00
01/18/18
01/18
09:00
01/18/18
09:00
Initiation
RA Pharmaceuticals initiated  »

RA Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:00
01/18/18
01/18
09:00
01/18/18
09:00
General news
The 41k initial claims drop to a 45-year low of 220k »

The 41k initial claims…

AGIO

Agios Pharmaceuticals

$70.33

1.53 (2.22%)

08:59
01/18/18
01/18
08:59
01/18/18
08:59
Recommendations
Agios Pharmaceuticals analyst commentary  »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 19

    Jan

PRTK

Paratek Pharmaceuticals

$17.68

-0.075 (-0.42%)

08:59
01/18/18
01/18
08:59
01/18/18
08:59
Syndicate
Paratek Pharmaceuticals 3.11M share Spot Secondary priced at $16.10 »

BTIG acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

ALXN

Alexion

$122.12

-2.36 (-1.90%)

08:59
01/18/18
01/18
08:59
01/18/18
08:59
Initiation
Alexion initiated  »

Alexion assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTZ

MasTec

$51.90

0.75 (1.47%)

08:59
01/18/18
01/18
08:59
01/18/18
08:59
Recommendations
MasTec analyst commentary  »

MasTec price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$57.18

0.25 (0.44%)

08:57
01/18/18
01/18
08:57
01/18/18
08:57
Downgrade
Continental Resources rating change  »

Continental Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GATX

GATX

$65.21

-0.5 (-0.76%)

08:57
01/18/18
01/18
08:57
01/18/18
08:57
Earnings
GATX reports Q4 non-GAAP EPS 68c, consensus 73c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

XLRN

Acceleron

$44.99

-0.03 (-0.07%)

08:57
01/18/18
01/18
08:57
01/18/18
08:57
Initiation
Acceleron initiated  »

Acceleron assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$231.37

2.83 (1.24%)

08:56
01/18/18
01/18
08:56
01/18/18
08:56
Hot Stocks
Becton Dickinson says enrollment complete in Lutonix below-the-knee trial »

BD announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 06

    Feb

SCHW

Charles Schwab

$56.09

0.56 (1.01%)

08:55
01/18/18
01/18
08:55
01/18/18
08:55
Recommendations
Charles Schwab analyst commentary  »

Charles Schwab price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$31.18

-0.06 (-0.19%)

, GE

General Electric

$17.35

-0.86 (-4.72%)

08:55
01/18/18
01/18
08:55
01/18/18
08:55
Options
Notable open interest changes for January 18th »

Wednesday's total…

BAC

Bank of America

$31.18

-0.06 (-0.19%)

GE

General Electric

$17.35

-0.86 (-4.72%)

FB

Facebook

$177.60

-0.79 (-0.44%)

BABA

Alibaba

$183.83

1.43 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 23

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 07

    Feb

  • 15

    Feb

  • 28

    Feb

08:55
01/18/18
01/18
08:55
01/18/18
08:55
General news
U.S. housing starts dropped 8.2% to 1.192 M in December »

U.S. housing starts…

ABM

ABM

$38.73

0.26 (0.68%)

08:55
01/18/18
01/18
08:55
01/18/18
08:55
Conference/Events
ABM to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.